PH27176A - Pharmaceutical compositions containing dipyridamole or mopidamole and O-acetylsalicyclic acid or the physiologically acceptable salts thereof - Google Patents

Pharmaceutical compositions containing dipyridamole or mopidamole and O-acetylsalicyclic acid or the physiologically acceptable salts thereof Download PDF

Info

Publication number: PH27176A
Authority: PH; Philippines
Prior art keywords: acid; dipyridamole; acceptable salts; mopidamol; acetylsalicylic acid
Prior art date: 1986-08-13

Application number

PH35653A

Other languages

English (en)

Inventor

Wolfgang Eisert

Peter Gruber

Original Assignee

Thomae Gmbh Dr K

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-13

Filing date

1987-08-11

Publication date

1993-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6307286&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH27176(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-08-11 Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K

1993-04-02 Publication of PH27176A publication Critical patent/PH27176A/en

Links

IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims abstract description 88
229960002768 dipyridamole Drugs 0.000 title claims abstract description 88
150000003839 salts Chemical class 0.000 title claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 57
FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 claims abstract description 22
229950010718 mopidamol Drugs 0.000 claims abstract description 22
239000002253 acid Substances 0.000 claims description 53
229960001138 acetylsalicylic acid Drugs 0.000 claims description 28
239000008188 pellet Substances 0.000 claims description 28
239000013543 active substance Substances 0.000 claims description 23
JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 19
239000002775 capsule Substances 0.000 claims description 14
239000004922 lacquer Substances 0.000 claims description 14
239000011248 coating agent Substances 0.000 claims description 13
238000000576 coating method Methods 0.000 claims description 13
230000035602 clotting Effects 0.000 claims description 12
230000000968 intestinal effect Effects 0.000 claims description 10
235000011389 fruit/vegetable juice Nutrition 0.000 claims description 9
230000003111 delayed effect Effects 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
238000009472 formulation Methods 0.000 claims description 6
210000004051 gastric juice Anatomy 0.000 claims description 6
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 5
-1 pyrimido-pyrimidine compound Chemical class 0.000 claims description 5
210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
239000012050 conventional carrier Substances 0.000 claims description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
229960004889 salicylic acid Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
235000007836 Chlorogalum pomeridianum Nutrition 0.000 claims 1
240000006670 Chlorogalum pomeridianum Species 0.000 claims 1
VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 claims 1
241001275899 Salta Species 0.000 claims 1
239000009895 amole Substances 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 abstract description 9
208000007536 Thrombosis Diseases 0.000 abstract description 4
230000002265 prevention Effects 0.000 abstract description 3
239000003826 tablet Substances 0.000 description 31
239000008187 granular material Substances 0.000 description 24
239000000126 substance Substances 0.000 description 16
238000002360 preparation method Methods 0.000 description 14
238000002474 experimental method Methods 0.000 description 13
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
230000009467 reduction Effects 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 9
230000000875 corresponding effect Effects 0.000 description 9
239000010410 layer Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
239000001267 polyvinylpyrrolidone Substances 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
210000004204 blood vessel Anatomy 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000008101 lactose Substances 0.000 description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
206010053567 Coagulopathies Diseases 0.000 description 6
230000002785 anti-thrombosis Effects 0.000 description 6
230000017531 blood circulation Effects 0.000 description 6
238000011049 filling Methods 0.000 description 6
238000005259 measurement Methods 0.000 description 6
238000000034 method Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000005755 formation reaction Methods 0.000 description 5
239000001530 fumaric acid Substances 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
238000011282 treatment Methods 0.000 description 5
210000003462 vein Anatomy 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
210000001772 blood platelet Anatomy 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000001035 drying Methods 0.000 description 4
230000009969 flowable effect Effects 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
230000000306 recurrent effect Effects 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000005303 weighing Methods 0.000 description 4
244000215068 Acacia senegal Species 0.000 description 3
239000001856 Ethyl cellulose Substances 0.000 description 3
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
229920003134 Eudragit® polymer Polymers 0.000 description 3
229920000084 Gum arabic Polymers 0.000 description 3
206010061216 Infarction Diseases 0.000 description 3
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
239000000205 acacia gum Substances 0.000 description 3
235000010489 acacia gum Nutrition 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
239000004411 aluminium Substances 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
235000019325 ethyl cellulose Nutrition 0.000 description 3
229920001249 ethyl cellulose Polymers 0.000 description 3
239000007941 film coated tablet Substances 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
230000007574 infarction Effects 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000004014 plasticizer Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
229940069575 rompun Drugs 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 3
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
238000013019 agitation Methods 0.000 description 2
210000000702 aorta abdominal Anatomy 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000001934 delay Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229960001123 epoprostenol Drugs 0.000 description 2
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229940094443 oxytocics prostaglandins Drugs 0.000 description 2
230000002688 persistence Effects 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
NOHUXXDTQJPXSB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 NOHUXXDTQJPXSB-UHFFFAOYSA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
101100205847 Mus musculus Srst gene Proteins 0.000 description 1
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000534944 Thia Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
AEMQUICCWRPKDB-UHFFFAOYSA-N acetic acid;cyclohexane-1,2-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1CCCCC1C(O)=O AEMQUICCWRPKDB-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
230000002744 anti-aggregatory effect Effects 0.000 description 1
239000002257 antimetastatic agent Substances 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
QSAWQNUELGIYBC-UHFFFAOYSA-N cyclohexane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCC1C(O)=O QSAWQNUELGIYBC-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
239000002874 hemostatic agent Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000007942 layered tablet Substances 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002254 renal artery Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003860 storage Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PH35653A 1986-08-13 1987-08-11 Pharmaceutical compositions containing dipyridamole or mopidamole and O-acetylsalicyclic acid or the physiologically acceptable salts thereof PH27176A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19863627423 DE3627423A1 (de)	1986-08-13	1986-08-13	Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung

Publications (1)

Publication Number	Publication Date
PH27176A true PH27176A (en)	1993-04-02

Family

ID=6307286

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH35653A PH27176A (en)	1986-08-13	1987-08-11	Pharmaceutical compositions containing dipyridamole or mopidamole and O-acetylsalicyclic acid or the physiologically acceptable salts thereof

Country Status (26)

Country	Link
US (1)	US6015577A (fr)
EP (1)	EP0257344B1 (fr)
JP (1)	JP2593879B2 (fr)
KR (1)	KR950009098B1 (fr)
AT (1)	ATE59961T1 (fr)
AU (1)	AU603146B2 (fr)
BR (1)	BR1100593A (fr)
CA (1)	CA1302272C (fr)
CL (1)	CL2004001252A1 (fr)
DD (1)	DD263918A5 (fr)
DE (3)	DE3627423A1 (fr)
DK (1)	DK172236B1 (fr)
ES (1)	ES2020974B3 (fr)
FI (1)	FI873492A (fr)
GR (1)	GR3001695T3 (fr)
HK (1)	HK14494A (fr)
HU (1)	HU202404B (fr)
IE (1)	IE60862B1 (fr)
IL (1)	IL83510A (fr)
NL (1)	NL990001I2 (fr)
NO (2)	NO175132C (fr)
NZ (1)	NZ221424A (fr)
PH (1)	PH27176A (fr)
PT (1)	PT85525B (fr)
SG (1)	SG122593G (fr)
ZA (1)	ZA875947B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19927689A1 (de) *	1999-06-17	2000-12-21	Gruenenthal Gmbh	Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
EP1093814A1 (fr) *	1999-10-22	2001-04-25	Boehringer Ingelheim Pharma KG	Utilisation du dipyridamole ou du mopidamol dans la fabrication d'un médicament pour le traitement et la prévention des troubles de la microcirculation dépendants de la fibrine
US7064130B2 (en) *	2001-04-20	2006-06-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20040058056A1 (en) *	2001-07-06	2004-03-25	Shigemasa Osaki	Drug diffusion coatings, applications and methods
WO2003030823A2 (fr) *	2001-10-05	2003-04-17	Combinatorx, Incorporated	Combinaisons permettant le traitement des troubles inflammatoires
TW200301135A (en) *	2001-12-27	2003-07-01	Otsuka Maryland Res Inst Inc	Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
US20030181488A1 (en) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10209982A1 (de) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma	Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US7485322B2 (en) *	2002-12-24	2009-02-03	Lek Pharmaceuticals D.D.	Modified release pharmaceutical composition
CA2515266A1 (fr) *	2003-02-07	2004-08-19	Boehringer Ingelheim International Gmbh	Utilisation du dipyridamole ou mopidamole pour le traitement et la prevention de troubles dependant de mmp-9
DE10306179A1 (de)	2003-02-13	2004-08-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
BRPI0409796A (pt) *	2003-04-24	2006-05-30	Boehringer Ingelheim Int	uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
US7041286B2 (en) *	2003-07-23	2006-05-09	Nerenberg Arnold P	Composition for mitigating a pernicious thrombotic event
TW200517114A (en) *	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
WO2005113006A2 (fr) *	2004-05-13	2005-12-01	Boehringer Ingelheim International Gmbh	Utilisation de dipyridamole pour le traitement de la resistance a des inhibiteurs plaquettaires
US9205054B2 (en)	2005-03-22	2015-12-08	Losan Pharma Gmbh	Solubilized ibuprofen
BRPI0614870A2 (pt) *	2005-08-22	2011-04-19	Novartis Ag	composições farmacêuticas
CA2640382C (fr)	2006-01-27	2015-12-29	Eurand, Inc	Systeme d'administration de medicaments comprenant des medicaments faiblement basiques et des acides organiques
CN103211779B (zh) *	2006-01-27	2016-03-16	阿代尔制药股份有限公司	包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送***
EP1820506B1 (fr) *	2006-02-09	2008-03-26	Teva Pharmaceutical Industries Ltd.	Compositions de dipyridamole à libération prolongée et leur procédé de préparation
WO2007139753A2 (fr) *	2006-05-22	2007-12-06	Combinatorx, Incorporated	Méthodes et compositions pour le traitement de maladies ou d'affections associées à des taux accrus de protéine c réactive, d'interleukine 6 ou d'interféron gamma
ITRM20060460A1 (it) *	2006-08-31	2006-11-30	Univ Roma	Uso di acido acetil salicilico in combinazione con inibitori dei canali mrp4 per il trattamento di pazienti resistenti a detto acido acetil salicilico
WO2008095263A1 (fr) *	2007-02-09	2008-08-14	Alphapharm Pty Ltd	Forme pharmaceutique contenant deux ou davantage de principes actifs pharmaceutiques sous des formes physiques différentes
CA2737131A1 (fr) *	2007-09-19	2009-03-26	Zalicus Inc.	Regimes therapeutiques pour le traitement de troubles immunoinflammatoires
CA2709561A1 (fr) *	2007-12-17	2009-06-25	Combinatorx, Incorporated	Regimes therapeutiques pour le traitement de troubles immuno-inflammatoires
WO2009097156A1 (fr) *	2008-02-01	2009-08-06	Barr Laboratories, Inc.	Capsules pharmaceutiques comprenant des granules de dipyridamole à libération prolongée
US8133506B2 (en) *	2008-03-12	2012-03-13	Aptalis Pharmatech, Inc.	Drug delivery systems comprising weakly basic drugs and organic acids
WO2009118321A1 (fr) *	2008-03-28	2009-10-01	Boehringer Ingelheim International Gmbh	Procédé de production de granules d'acide
US20100080846A1 (en) *	2008-09-25	2010-04-01	Avshalom Ben-Menachem	Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20110003005A1 (en) *	2009-07-06	2011-01-06	Gopi Venkatesh	Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2361615A1 (fr)	2010-02-19	2011-08-31	Alfred E. Tiefenbacher GmbH & Co. KG	Comprimé à libération prolongée de dipyridamole
JP2014517843A (ja) *	2011-05-24	2014-07-24	テバファーマシューティカルインダストリーズリミティド	医薬組成物用の圧縮コア
CN103239724A (zh) *	2013-05-27	2013-08-14	成都自豪药业有限公司	抗血栓形成的联合用药物及其药物组合物
ES2974674T3 (es) *	2017-06-19	2024-07-01	Cleveland Clinic Found	Tratamiento de enfermedades y promoción de la pérdida de peso inhibiendo la vía TMA/FMO3/TMAO

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2368280A1 (fr) *	1976-10-20	1978-05-19	Theramex	Nouvelle composition therapeutique presentant une activite anti-agregante plaquettaire, et son procede de preparation
FR2368272A1 (fr) *	1976-10-20	1978-05-19	Theramex	Compositions therapeutiques solides pour combattre l'agregation plaquettaire
LU77353A1 (fr) *	1977-05-16	1979-01-19
DE3000979A1 (de) *	1980-01-12	1981-07-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
FR2513118A1 (fr) *	1981-09-18	1983-03-25	Rocador Sa	Composition pharmaceutique a base de dipyridamol et de sel d'aluminium de l'acide acetylsalicylique pour combattre l'agregation plaquettaire
ATE50497T1 (de) *	1984-07-21	1990-03-15	Hoechst Ag	Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.

1986
- 1986-08-13 DE DE19863627423 patent/DE3627423A1/de not_active Withdrawn
1987
- 1987-07-31 AT AT87111104T patent/ATE59961T1/de active
- 1987-07-31 DE DE2002199015 patent/DE10299015I2/de active Active
- 1987-07-31 EP EP87111104A patent/EP0257344B1/fr not_active Expired - Lifetime
- 1987-07-31 ES ES87111104T patent/ES2020974B3/es not_active Expired - Lifetime
- 1987-07-31 DE DE8787111104T patent/DE3767408D1/de not_active Expired - Lifetime
- 1987-08-11 DD DD87305901A patent/DD263918A5/de not_active IP Right Cessation
- 1987-08-11 PH PH35653A patent/PH27176A/en unknown
- 1987-08-11 CA CA000544180A patent/CA1302272C/fr not_active Expired - Lifetime
- 1987-08-12 NO NO873370A patent/NO175132C/no not_active IP Right Cessation
- 1987-08-12 ZA ZA875947A patent/ZA875947B/xx unknown
- 1987-08-12 IE IE215287A patent/IE60862B1/en not_active IP Right Cessation
- 1987-08-12 AU AU76795/87A patent/AU603146B2/en not_active Expired
- 1987-08-12 IL IL83510A patent/IL83510A/xx not_active IP Right Cessation
- 1987-08-12 PT PT85525A patent/PT85525B/pt unknown
- 1987-08-12 DK DK421187A patent/DK172236B1/da not_active IP Right Cessation
- 1987-08-12 NZ NZ221424A patent/NZ221424A/xx unknown
- 1987-08-12 FI FI873492A patent/FI873492A/fi not_active Application Discontinuation
- 1987-08-12 HU HU873652A patent/HU202404B/hu unknown
- 1987-08-12 JP JP62201688A patent/JP2593879B2/ja not_active Expired - Lifetime
- 1987-08-13 KR KR87008873A patent/KR950009098B1/ko not_active IP Right Cessation
1991
- 1991-03-29 GR GR91400406T patent/GR3001695T3/el unknown
1993
- 1993-11-11 SG SG122593A patent/SG122593G/en unknown
1994
- 1994-02-24 HK HK144/94A patent/HK14494A/xx not_active IP Right Cessation
1995
- 1995-04-12 US US08/421,351 patent/US6015577A/en not_active Expired - Lifetime
1997
- 1997-05-13 BR BR1100593-9A patent/BR1100593A/pt active IP Right Grant
1999
- 1999-01-06 NL NL990001C patent/NL990001I2/nl unknown
- 1999-07-01 NO NO1999014C patent/NO1999014I1/no unknown
2004
- 2004-05-24 CL CL200401252A patent/CL2004001252A1/es unknown

Also Published As

Publication number	Publication date
NZ221424A (en)	1989-11-28
US6015577A (en)	2000-01-18
HU202404B (en)	1991-03-28
FI873492A (fi)	1988-02-14
AU7679587A (en)	1988-02-18
BR1100593A (pt)	2002-04-02
SG122593G (en)	1994-06-10
AU603146B2 (en)	1990-11-08
DE10299015I2 (de)	2005-06-16
PT85525B (pt)	1990-06-29
PT85525A (de)	1987-09-01
KR880002529A (ko)	1988-05-09
DE10299015I1 (de)	2002-10-10
ZA875947B (en)	1989-04-26
NO175132C (no)	1994-09-07
JPS6348219A (ja)	1988-02-29
DE3767408D1 (de)	1991-02-21
JP2593879B2 (ja)	1997-03-26
NO175132B (no)	1994-05-30
DD263918A5 (de)	1989-01-18
IE872152L (en)	1988-02-13
CA1302272C (fr)	1992-06-02
FI873492A0 (fi)	1987-08-12
HUT44937A (en)	1988-05-30
EP0257344B1 (fr)	1991-01-16
HK14494A (en)	1994-03-04
ES2020974B3 (es)	1991-10-16
NO873370D0 (no)	1987-08-12
GR3001695T3 (en)	1992-11-23
DK421187D0 (da)	1987-08-12
NO873370L (no)	1988-02-15
DE3627423A1 (de)	1988-02-18
IL83510A (en)	1992-02-16
CL2004001252A1 (es)	2005-03-04
IL83510A0 (en)	1988-01-31
NO1999014I1 (no)	1999-07-01
DK421187A (da)	1988-02-14
IE60862B1 (en)	1994-08-24
KR950009098B1 (en)	1995-08-14
NL990001I1 (nl)	1999-03-01
NL990001I2 (nl)	2000-04-03
DK172236B1 (da)	1998-02-02
EP0257344A1 (fr)	1988-03-02
ATE59961T1 (de)	1991-02-15

Publication	Publication Date	Title
CA1302272C (fr)	1992-06-02	Compositions pharmaceutiques contenant du dipyridamole ou du mopidamoi ou de l'acide o-acetylsalycylique ou des sels physiologiquement acceptables de ceux-ci, procede pour leur preparation et leur utilisation pour le traitement de formation de caillots
US4066756A (en)	1978-01-03	Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin
DK170922B1 (da)	1996-03-18	Cefaclorformulering med langvarig virkning
EP0277127B1 (fr)	1991-04-10	Nouvelle preparation medicamenteuse a liberation controlee de l'ingredient actif,et son procede de fabrication
KR100949273B1 (ko)	2010-03-25	복합제제
EP0431877B1 (fr)	1994-10-19	Compositions pharmaceutiques à base de cimétidine
US4968505A (en)	1990-11-06	Long-acting diclofenac sodium preparation
US4948581A (en)	1990-08-14	Long acting diclofenac sodium preparation
US20100330174A1 (en)	2010-12-30	Betaine compositions
KR101207618B1 (ko)	2012-12-04	심혈관계 질환 치료용 약제학적 제제
KR100955669B1 (ko)	2010-05-06	ＨＭＧＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법
MXPA01013047A (es)	2002-06-04	Tableta multicapa para la administracion de una combinacion fija de tramdol y diclofenac.
IE59053B1 (en)	1993-12-15	Controlled release metoprolol preparations
NZ201008A (en)	1985-11-08	Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
CZ454090A3 (en)	1996-11-13	Pharmaceutical preparations for preventing and/or treating myocardial heart attack or brain apoplexy of mammals
IE833026L (en)	1985-06-21	Controlled absorption pharmaceutical formulation
US4690927A (en)	1987-09-01	Pharmaceutical compositions with analgesic properties and the preparation and use thereof
US4600577A (en)	1986-07-15	Pharmaceutical preparations of pinacidal
KR20190092805A (ko)	2019-08-08	아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물
CA1099641A (fr)	1981-04-21	Traduction non-disponible
CN102247366B (zh)	2015-04-15	包括依那普利和非洛地平的药物组合物缓释制剂
EA007571B1 (ru)	2006-12-29	Микрокапсулы для отсроченного и регулируемого высвобождения периндоприла
RU2316328C1 (ru)	2008-02-10	Способ коррекции частичного возрастного андрогенного дефицита (padam) и препаративная форма тестостерона или его фармакологически приемлемых производных для его осуществления